RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

NCT01317615 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Large Cell
Neuroendocrine Tumors

Interventions

DRUG: RAD001
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Novartis Pharmaceuticals